Abstract:New drugs being established in the market every year produce specified structures for selective biological targeting. With medicinal insights into molecular recognition, these begot molecules open new rooms for designing potential new drug molecules. In this review, we report the compilation and analysis of a total of 56 drugs including 33 organic small molecules (Mobocertinib, Infigratinib, Sotorasib, Trilaciclib, Umbralisib, Tepotinib, Relugolix, Pralsetinib, Decitabine, Ripretinib, Selpercatinib, Capmatinib, Pemigatinib, Tucatinib, Selumetinib, Tazemetostat, Avapritinib, Zanubrutinib, Entrectinib, Pexidartinib, Darolutamide, Selinexor, Alpelisib, Erdafitinib, Gilteritinib, Larotrectinib, Glasdegib, Lorlatinib, Talazoparib, Dacomitinib, Duvelisib, Ivosidenib, Apalutamide), 6 metal complexes (Edotreotide Gallium Ga-68, fluoroestradiol F-18, Cu 64 dotatate, Gallium 68 PSMA-11, Piflufolastat F-18, 177Lu (lutetium)), 16 macromolecules as monoclonal antibody conjugates (Brentuximabvedotin, Amivantamab-vmjw, Loncastuximabtesirine, Dostarlimab, Margetuximab, Naxitamab, Belantamabmafodotin, Tafasitamab, Inebilizumab, SacituzumabGovitecan, Isatuximab, Trastuzumab, Enfortumabvedotin, Polatuzumab, Cemiplimab, Mogamulizumab) and 1 peptide enzyme (Erwiniachrysanthemi-derived asparaginase) approved by the U.S. FDA between 2018 to 2021. These drugs act as anticancer agents against various cancer types, especially non-small cell lung, lymphoma, breast, prostate, multiple myeloma, neuroendocrine tumor, cervical, bladder, cholangiocarcinoma, myeloid leukemia, gastrointestinal, neuroblastoma, thyroid, epithelioid and cutaneous squamous cell carcinoma. The review comprises the key structural features, approval times, target selectivity, mechanisms of action, therapeutic indication, formulations, and possible synthetic approaches of these approved drugs. These crucial details will benefit the scientific community for futuristic new developments in this arena.

Unlocking the synthetic approaches and clinical application of approved small-molecule drugs for gastrointestinal cancer treatment: A comprehensive exploration

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas

An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021)

Synthetic routes and clinical application of Small-Molecule HER2 inhibitors for cancer therapy

Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics

Reviewing the Synthesis and Clinical Application of FDA-Approved Anticancer Medications

Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer

Synthetic Strategies to Glycosylated Nitrogen-Containing Heterocyclic Compounds with Potential Anticancer Activities

Promising therapeutics of gastrointestinal cancers in clinical trials

Synthetic Approaches and Clinical Application of Representative Small-Molecule Inhibitors of Cyclin-Dependent Kinase for Cancer Therapy

An update of new small-molecule anticancer drugs approved from 2015 to 2020

Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges

Small Molecule Inhibitors Targeting the Cancers

Using omics approaches to dissect the therapeutic effects of Chinese herbal medicines on gastrointestinal cancers

Small molecule anticancer drugs approved during 2021-2022: Synthesis and clinical applications

Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy

Unveiling promising targets in gastric cancer therapy: A comprehensive review

Small-Molecule Targets in Immuno-Oncology

OMICS Applications for Medicinal Plants in Gastrointestinal Cancers: Current Advancements and Future Perspectives

Therapeutic Target for Gastrointestinal Cancers